TORONTO, March 4, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, announced today that the Company will host a Toronto reception on Thursday, March 7 to announce Cannamexico World Summit 2019, one of the largest and most influential cannabis conferences in Latin America. The Toronto reception will introduce the summit agenda, the first Canadian Pavilion and feature an exclusive on-stage Q&A with Mr. Vicente Fox, the 55th President of Mexico, and former CEO of Coca Cola Mexico.
WHO: Khiron Life Sciences and CentroFox
WHAT: Cannamexico World Summit 2019 Launch
WHERE: | St.Regis Hotel, 325 Bay Street, Toronto
WHEN: | Thursday March 7, 12:30pm – 2:00pm
This event is for invited guests and media. Luncheon will be served.
Q&A Highlights: Mr. Fox will discuss opportunities in Mexico's cannabis industry, offer an outlook on the global industry and how cannabusinesses can continue to build ties between Canada, Mexico and across Latin America. The on-stage Q&A with Mr. Fox will be available on livestream at https://www.meetview.com/khiron20190307/
The Cannamexico World Summit 2019, taking place April 25-26 in Guanajuato, Mexico, will bring together more than 2,000 attendees from across the region, connecting the cannabis community with national and international experts on priority topics, including; regulatory affairs, eco-growth and sustainability, medicine and science, pain reduction and industry growth opportunities. For the first time, Khiron and Cannamexico will host The Canadian Pavilion, a significant on-site space dedicated to showcasing Canada's leading cannabis and related companies engaged in developing business growth opportunities in Mexico.
Vicente Fox, the 55th President of Mexico, former CEO of Coca-Cola Mexico, and founder of CentroFox, stated, "The cannabis industry has the potential to be a pillar of our economies, and as legislation progresses across Latin America I invite attendees to Cannamexico 2019, a global summit that will bring together the worlds cannabis community to debate responsible and commercially successful developments in Mexico and across the region."
Khiron is strategically positioned to enter the Mexican market. As previously announced, Khiron's Mexico subsidiary has received approval to commercialize three products from Khiron's nutraceutical product line, it is set up in the country to submit license applications, and has initiated an in-depth regulatory review of the country's legal medical cannabis landscape as well as an assessment of market needs. The commencement of sales in Mexico is subject to prior TSX Venture Exchange ("TSXV") approval. Mexico comprises a population of approximately 124 million people, with nearly 11.7 million potential patients for medical cannabis.
Presented by CentreFox and Khiron Life Sciences, Cannamexico is a global summit focused on showcasing the potential for the Cannabis industry in Mexico, a market estimated at 2 Billion USD (Source: Prohibition Partners). The summit brings together regional and global cannabis leaders to discuss regulatory developments, market opportunities, medical advances, innovation, and wellness for the LatAm cannabis industry.
For more information visit the website: http://cannamexico.com.mx/en
Khiron Life Sciences Corp. is positioned to be the dominant integrated medical cannabis company in Latin America. Khiron has core operations in Latin America and is fully licensed in Colombia for the cultivation, production, domestic distribution, and international export of both THC (tetrahydrocannabinol) and CBD (cannabidiol) medical cannabis. In May 2018, Khiron listed on the TSX Venture Exchange, becoming the first Colombian based medical cannabis companies to trade on any exchange globally.
With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. Khiron is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox.
Further information on Khiron Life Sciences can be found at https://investors.khiron.ca/
Market and Industry Data
This press release contains market and industry data and forecasts that were obtained from third-party sources, industry publications and publicly available information. Third-party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there can be no assurance as to the accuracy or completeness of included information. Although management believes it to be reliable, the Company has not independently verified any of the data from third-party sources referred to in this press release, or analyzed or verified the underlying studies or surveys relied upon or referred to by such sources, or ascertained the underlying economic assumptions relied upon by such sources.
This press release may contain certain "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Forward-looking statements may be identified by statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Forward-looking statements herein include, but are not limited to, statements regarding the final acceptance of the TSXV and the commencement of sales in Mexico. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. Khiron undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Annual Information Form which is available on Khiron's SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
SOURCE Khiron Life Sciences Corp.
For further information: Investor Contacts: Chris Naprawa, President, T: +1 (416) 705-1144, E: [email protected]; Media Contact: Jon Packer, Vice President, Communications, T: +1 (416) 543-9179, E: [email protected]